Physician profile
Karyn D Asher
NPI 1952780447
$328.43
in general payments reported to CMS, 2019-2025
14 companies · $79.53 in 2025
The $79.53 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.28 · 2022: $54.50 · 2023: $69.58 · 2024: $69.54 · 2025: $79.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $54.19 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $38.11 | 2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $31.43 | 2024 | |
| Hologic Sales and Service, LLC | $27.00 | 2022 | |
| Abbott Laboratories | $22.81 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $21.75 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $21.04 | 2021 | |
| Sanofi Pasteur INC. | $19.95 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.73 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $18.18 | 2023 | Ingrezza |
| Glaxosmithkline, LLC. | $15.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.29 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.45 | 2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karyn Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.